A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Clinical trial NCT03845166 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03845166
Sponsor: Exelixis
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasm Malignant Renal Cell Carcinoma Hormone Receptor Positive Breast Carcinoma Metastatic Castration-resistant Prostate Cancer Colorectal Cancer

Start date: 2019-03-20
Primary completion: 2026-08-31
Enrollment: 325

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.